Age related macular degeneration and visual disability

Current Drug Targets

Volumn 12, Issue 2, 2011, Pages 221-233

  Christoforidis, John B ^a   Tecce, Nicola ^b   dell'Omo, Roberto ^b   Mastropasqua, Rodolfo ^b   Verolino, Marco ^c   Costagliola, Ciro ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MOLISE   (Italy)

^c Azienda Sanitaria di Rilievo Nazionale ed Alta   (Italy)

Author keywords

Age related macular degeneration; Epidemiology; Magnifying glasses; Prescription filters; Risk factors; Telescopes and electronic aids; Visual disability

Indexed keywords

ARTICLE; CENTRAL SCOTOMA; DAILY LIFE ACTIVITY; HUMAN; LOW VISION REHABILITATION; OPTICAL COHERENCE TOMOGRAPHY; REHABILITATION; RETINA MACULA AGE RELATED DEGENERATION; VISUAL ACUITY; VISUAL DISORDER; VISUAL IMPAIRMENT; BLINDNESS; PATHOPHYSIOLOGY; PATIENT; RETINA MACULA DEGENERATION;

ACTIVITIES OF DAILY LIVING; BLINDNESS; HUMANS; MACULAR DEGENERATION; VISION, LOW; VISUALLY IMPAIRED PERSONS;

EID: 79955672256     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011794182755     Document Type: Article

References (69)

1. van Newkirk MR, Nanjan MB, Wang JJ, et al. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000; 107: 1593-600.
2. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia. The blue mountains eye study. Ophthalmology 1996; 103: 357-64.
3. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450-60.
4. Newland HS, Hiller JE, Casson RJ, Obermeder S. Prevalence and causes of blindness in the South Australian population aged 50 and over. Ophthalmic Epidemiol 1996; 3: 97-107.
5. Klein R, Wang Q, Klein BEK, et al. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995; 36: 182-91.
6. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med 1991; 325: 1412-7.
7. Bressler NM, Bressler SB, West SK, et al. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 1989; 107: 847-52.
8. Evans J. Causes of blindness and partial sight in England and Wales. Studies on medical and population subjects No. 57. London: Her Majesty's Stationary Office 1995.
9. Kaur C, Foulds WS, Ling EA. Hypoxia-ischemia and retinal ganglion cell damage. Clin Ophthalmol 2008; 2: 879-89.
10. Young RW. Pathophysiology of age-related macular degeneration. Surv Ophthalmol 1987; 31: 291-306.
11. Green WR. Histopathology of age-related macular degeneration. Mol Vis 1999; 5: 27.
12. Espinosa-Heidmann DG, Marin-Castano ME, Pereira-Simon S, et al. Gender and estrogen supplementation increases severity of experimental choroidal neovascularization. Exp Eye Res 2005; 80: 413-23.
13. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116: 653-8.
14. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32: 375-413.
15. Roh MI, Kim HS, Song JH, et al. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with AMD after bevacizumab treatment. Retina 2009; 29: 523-9.
16. World Health Organization. International statistical classification of diseases, injuries and causes of death, tenth revision. Geneva: WHO 1993.
17. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-51.
18. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001; 108: 697-704.
19. Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related macular degeneration. Lancet 2008; 372: 1835-45.
20. Bressler SB, Muñoz B, Solomon SD, West SK. Salisbury Eye Evaluation (SEE) Study Team. Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol 2008; 126: 241-5.
21. Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains eye study. Aust NZ J Ophthalmol 1997; 25: S13-5.
22. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007; 357: 553-61.
23. Chang MA, Bressler SB, Munoz B, West SK. Racial differences and other risk factors for incidence and progression of age-related macular degeneration: Salisbury Eye Evaluation (SEE) Project. Invest Ophthalmol Vis Sci 2008; 49: 2395-402.
24. Costagliola C, Libondi T, Menzione M, et al. Vitamin E and red blood cell glutathione. Metabolism 1985; 34: 712-4.
25. Costagliola C, Cotticelli L, Rosolia S, et al. Red cell glutathione as a marker of tobacco smoke-induced optic neuropathy. Exp Eye Res 1989; 48: 583-89.
26. Costagliola C, Cotticelli L, Menzione M, et al. Red blood cell glutathione and tobacco smoke-induced optic neuropathy. Metab Ped Syst Ophthalmol 1990; 13: 96-9.
27. Taylor HR, Munoz B, West S, et al. Visible light and risk of agerelated macular degeneration. Transactions of the American Ophthalmol Soc 1990; 997: 163-73.
28. Taylor HR, West S, Muñoz B, et al. The long-term effects of visible light on the eye. Arch Ophthalmol 1992; 110: 99-104.
29. AREDS. A randomized, placebo-controlled, clinical trial of highdose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 1417-36.
30. Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in Medicare neovascular agerelated macular degeneration patients. Ophthalmology 2007; 114: 2174-8.
31. Liew G, Mitchell P, Wong TY, et al. CKD Increases the Risk of Age-Related Macular Degeneration. J Am Soc Nephrol 2008; 19: 806-11.
32. Kawasaki R, Wang JJ, Ji GJ, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population the funagata study. Ophthalmology 2008; 115: 1376-81.
33. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 1998; 116: 583-7.
34. Delcourt C, Michel F, Colvez A, et al. Associations of cardiovascular disease and its risk factors with age related macular degeneration: the POLA study. Ophthalmic Epidemiol 2001; 8: 237-49.
35. Klein B, Klein R, Lee K, Jensen S. Measures of obesity and agerelated eye diseases. Ophthalmic Epidemiol 2001; 8: 251-62.
36. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol 2003; 121: 785-92.
37. Peeters A, Magliano DJ, Stevens J, Duncan BB, Klein R, Wong TY. Changes in abdominal obesity and age-related macular degeneration: the Atherosclerosis Risk in Communities Study. Arch Ophthalmol 2008; 126: 1554-60.
38. Arden GB, Wolf JE. Colour vision testing as an aid to diagnosis and management of age related maculopathy. Br J Ophthalmol 2004; 88: 1180-5.
39. Fletcher DC, Schuchard RA. Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity. Optom Vis Sci 2006; 83: 178-89.
40. Massin P, Girach A, Erginay A, Gaudric A. Optical coherence tomography: a key to the future management of patients with diabetic macular oedema. Acta Ophthalmol Scand 2006; 84: 466-74.
41. Joeres S, Tsong JW, Updike PG, et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48: 4300-7.
42. Kramer M, Mimouni K, Priel E, Yassur Y, Weinberger D. Comparison of fluorescein angiography and indocyanine green angiography for imaging of choroidal neovascularization in hemorrhagic age-related macular degeneration. Am J Ophthalmol 2000; 129: 495-500.
43. Hassenstein A, Meyer CH. Clinical use and research applications of Heidelberg retinal angiography and spectral-domain optical coherence tomography-a review. Clin Experiment Ophthalmol 2009; 37: 130-43.
44. Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 2007; 15: 174-82.
45. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009; 28: 1-18.
46. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003; 121: 1621-24.
47. Tan JS, Wang JJ, Flood V, Rochtchina E, Smith W, Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2008; 115: 334-41.
48. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008; 358: 2606-17.
49. Reeves BC, Harper RA, Russell WB. Enhanced low vision rehabilitation for people with age related macular degeneration: a randomised controlled trial. Br J Ophthalmol 2004; 88: 1443-9.
50. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol 1999; 128: 45-53.
51. Banerjee A, Kumar S, Kulhara P, Gupta A. Prevalence of depression and its effect on disability in patients with age-related macular degeneration. Indian J Ophthalmol 2008; 56: 469-74.
52. Birk T, Hickl S, Wahl HW, et al. Development and pilot evaluation of a psychosocial intervention program for patients with agerelated macular degeneration. Gerontologist 2004; 44: 836-43.
53. Virgili G, Acosta R. Reading aids for adults with low vision. Cochrane Database Syst Rev 2006; (4): CD003303.
54. Kleen SR, Levoy RJ. Low-vision care: Correlation of patient age, visual goals, and aids prescribed. Am J Optom Physiol Opt 1981; 58: 200-5.
55. Whittaker SG, Budd J, Cummings RW: Eccentric fixation with macular scotoma. Invest Ophthalmol Vis Sci 1988; 29: 268-78.
56. Déruaz A, Goldschmidt M, Whatham AR, et al. A technique to train new oculomotor behavior in patients with central macular scotomas during reading related tasks using scanning laser ophthalmoscopy: immediate functional benefits and gains retention. BMC Ophthalmol 2006; 23: 6-35.
57. Timberlake GT, Peli E, Essock EA, Augliere RA. Reading with a macular scotoma. II. Retinal locus for scanning text. Invest Ophthalmol Vis Sci 1987; 28: 1268-74.
58. Gohdes DM, Balamurugan A, Larsen BA, Maylahn C. Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2005; 2: A17
59. Markowitz SN. Principles of modern low vision rehabilitation. Can J Ophthalmol 2006; 41: 289-312.
60. Lowe JB, Rubinstein MP. Distance telescopes: a survey of user success. Optom Vis Sci 2000; 77: 260-9.
61. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 1998; 43: 134-46.
62. Cruickshanks K, Klein R, Klein B. Sunlight and age-related macular degeneration. The Beaver Dam Eye Study. Arch Ophthalmol 1993; 111: 514-8.
63. Mares Perlman J, Brady W, Klein R, et al. Serum antioxidants and age-related macular degeneration in a population based case control study. Arch Ophthalmol 1995; 113: 1518-23.
64. Christen W, Glynn R, Manson J, et al. A prospective study of cigarette smoking and risk in age-related macular degeneration in men. JAMA 1996; 276: 1147-51.
65. Hogg RE, Chakravarthy U. Visual function and dysfunction in early and late age-related maculopathy. Prog Retin Eye Res 2006; 25: 249-76.
66. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic atrophy of the retinal pigment epithelium. Eye 1988; 2: 552-77.
67. Mayer MJ, Ward B, Klein R, et al. Flicker sensitivity and fundus appearance in pre-exudative age-related maculopathy. Invest Ophthalmol Vis Sci 1994; 35: 1138-49.
68. Lovie-Kitchin JE, Brown B. Repeatability and intercorrelations of standard vision tests as a function of age. Optom Vis Sci 2000; 77: 412-20.
69. Comer GM, Ciulla TA, Criswell MH, Tolentino M. Current and future treatment options for non neovascular and neovascular age related macular degeneration. Drugs Aging 2004; 21: 967-92.